NEW YORK – Longevity Health Holdings announced Monday that it has merged with laboratory testing firm 20/20 BioLabs in an all-stock transaction.
Pittsburgh-based Longevity said the merger with Gaithersburg, Maryland-based 20/20 advances its efforts to develop its diagnostics business and will have synergies with its bio-aesthetic product portfolio and a possible expansion into nutrition. The deal follows Longevity’s acquisition of Elevai Skincare in January.
Longevity’s focus is human longevity and healthy aging, while 20/20 specializes in laboratory testing for the early detection and management of chronic disease. 20/20 operates a Gaithersburg-based CLIA laboratory out of which it offers its $200 OneTest multi-cancer early detection blood test, which tests for more than a dozen cancer types including lung, pancreatic, ovarian, and liver cancer.
20/20 plans in coming months to launch a "longevity test" that analyzes inflammatory biomarkers linked to chronic disease and unhealthy aging. The product will also include diet and lifestyle recommendations.
Following the close of the merger, pre-merger 20/20 stockholders will own approximately 50.1 percent of the company and pre-merger Longevity stockholders will own approximately 49.9 percent of the company. The percentage of the combined company owned by pre-merger 20/20 stockholders could increase dependent on the achievement of earnout milestones.
Rajiv Shukla, chairman and CEO of Longevity, will remain chairman while 20/20 CEO Jonathan Cohen will be CEO of the combined company. The company will continue to trade on the Nasdaq under Longevity's current symbol XAGE.
The post-closing equity value of the combined company is expected to be approximately $99 million with anticipated 2025 revenue of $7 million to $8 million. The company expects to achieve more than $1 million in operational savings and synergies in fiscal year 2025.
"We are excited by the market, product, and operational synergies between 20/20 and Longevity," Cohen said in a statement. "We believe 20/20 is a leader in offering access to lab testing in nontraditional settings, such as homes and retail locations. We expect this merger will expand our reach to med spas and other channels covered by Longevity’s existing customer base."
"We are happy to announce a merger with 20/20 in line with our previously announced corporate rebranding and acquisition strategy," Shukla said in a statement. "This merger is expected to double our fiscal-year 2025 revenue forecast and put us on the path to profitability."
The merger is expected to close in Q3 2025.